GEN Exclusives

More »

GEN News Highlights

More »
Aug 24, 2012

Failed Alzheimer’s Disease mAb Not Quite Dead

  • Eli Lilly says it hasn’t yet decided on the future of its Alzheimer’s disease (AD) candidate solanezumab, despite the drug failing to meet either cognitive or functional primary endpoints in both of its Phase III Expedition trials in patients with mild-to-moderate disease. The firm is clinging onto data emerging from a prespecified secondary analysis of pooled results from both the Expedition1 and Expedition2 trials, which showed that treatment with the anti-amyloid beta monoclonal antibody solanezumab resulted in a statistically significant slowing of cognitive decline in patients with mild AD, but not those with moderate AD.

    Lilly says these findings are the first from a Phase III study to indicate that an anti-beta amyloid agent may help slow cognitive decline. “We recognize that the solanezumab studies did not meet their primary endpoints, but we are encouraged by the pooled data that appear to show a slowing of cognitive decline,” comments John C. Lechleiter, Ph.D., chairman, president and CEO. “We intend to discuss these data with regulatory authorities to gain their insights on potential next steps.”

    The two 18-month placebo-controlled Expedition studies included over 2,050 patients with mild-to-moderate AD in 16 countries. An open-label extension to the studies is now fully enrolled and will continue, Lilly states.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »